Advertisement
Screener

IVERIC bio, Inc. Patents: Applications Rejected

IVERIC bio, Inc. Patent Applications Rejected

17 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2023-04-07: Application 18132315; Invention ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD; Applicant IVERIC bio, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2023-04-07: Application 18132253; Invention METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS; Applicant IVERIC bio, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2023-02-08: Application 18107251; Invention METHOD FOR TREATING OR PREVENTING IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV); Applicant IVERIC bio, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2022-10-03: Application 17958710; Invention METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS; Applicant IVERIC bio, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2023-04-0718132315ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMDIVERIC bio, Inc.Abandoned -- Failure to Respond to an Office ActionUS20240139328A1
Kourous A. Rezaei
United States
MILLER, DALE R
2023-04-0718132253METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONSIVERIC bio, Inc.Abandoned -- Failure to Respond to an Office ActionUS20230364122A1
Samir Patel
Richard Everett
Douglas Brooks
Shane Xinxin Tian
United States
United States
United States
United States
WHITEMAN, BRIAN A
2023-02-0818107251METHOD FOR TREATING OR PREVENTING IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)IVERIC bio, Inc.Abandoned -- Failure to Respond to an Office ActionUS20240000889A1
Kourous Rezaei
United States
BORGEEST, CHRISTINA M
2022-10-0317958710METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONSIVERIC bio, Inc.Abandoned -- Failure to Respond to an Office ActionUS20250000889A1
Samir Patel
Richard Everett
Douglas Brooks
Shane Xinxin Tian
United States
United States
United States
United States
LOCKARD, JON MCCLELLAND
2019-06-0616434018METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONSIVERIC bio, Inc.Abandoned -- Failure to Respond to an Office ActionUS20190381087A1
Samir Patel
Richard Everett
Douglas Brooks
Shane Xinxin Tian
United States
United States
United States
United States
VIVLEMORE, TRACY ANN
2016-05-0215144429Methods for Treating or Preventing Ophthalmological ConditionsOphthotech CorporationAbandoned -- Failure to Respond to an Office ActionUS20160296550A1
Samir Patel
Richard Everett
Douglas Brooks
Shane Xinxin Tian
United States
United States
United States
United States
VIVLEMORE, TRACY ANN
2015-10-2014918047METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASESOPHTHOTECH CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20160264969A1
Samir Patel
Harvey Masonson
United States
United States
HUYNH, PHUONG N
2015-08-0714821333METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONSOphthotech CorporationAbandoned -- Failure to Respond to an Office ActionUS20160038589A1
Samir Patel
United States
HAMA, JOANNE
2015-01-3014610332COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERSOPHTHOTECH CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20150202289A1
David Shima
Perry Calias
Anthony P. Adamis
United Kingdom
United States
United States
HUYNH, PHUONG N
2015-01-1614598365Combination Therapy for the Treatment of Ocular Neovascular DisordersOPHTHOTECH CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20150202288A1
DAVID SHIMA
PERRY CALIAS
ANTHONY P. ADAMIS
United Kingdom
United States
United States
HUYNH, PHUONG N
2014-11-2614554894Compositions Comprising an Anti-PDGF Aptamer and a VEGF AntagonistOphthotech CorporationAbandoned -- Failure to Respond to an Office ActionUS20150182623A1
Richard Everett
Byeong Seon Chang
United States
United States
SCHNIZER, RICHARD A
2014-10-2314522360Compositions Comprising an Anti-PDGF Aptamer and a VEGF AntagonistOPHTHOTECH CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20150157709A1
RICHARD EVERETT
BYEONG SEON CHANG
United States
United States
HUYNH, PHUONG N
2014-07-1114329702Methods for Treating or Preventing Ophthalmological ConditionsOphthotech CorporationAbandoned -- Failure to Respond to an Office ActionUS20150017163A1
Samir Patel
United States
LOCKARD, JON MCCLELLAND
2014-06-1314303973COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERSOPHTHOTECH CORPORATIONAbandoned -- Failure to Respond to an Office ActionUS20140294816A1
David Shima
Perry Calias
Anthony P. Adamis
United Kingdom
United States
United States
HUYNH, PHUONG N
2014-02-2114186149COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERSOphthotech CorporationAbandoned -- Failure to Respond to an Office ActionUS20140242082A1
David Shima
Perry Calias
Anthony P. Adamis
United Kingdom
United States
United States
HUYNH, PHUONG N
2013-08-0913963872Methods for Treating or Preventing Ophthalmological DiseasesOphthotech CorporationAbandoned -- Failure to Respond to an Office ActionUS20140179621A1
Samir Patel
Harvey Masonson
United States
United States
HUYNH, PHUONG N
2013-03-1213797821COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONISTOPHTHOTECH CORP.Abandoned -- Failure to Respond to an Office ActionUS20130323242A1
Richard Everett
Byeong Seon Chang
United States
United States
HUYNH, PHUONG N